No Detail Found!

Impact of episodic treatment of paroxetine on depressive-like behavior and anorexia in rat model of unpredictable stress

Author(s)
Muhammad Farhan Neurochemistry and Biochemical Neuropharmacology Research Unit, Department of Biochemistry, University of Karachi, Karachi, Pakistan.
Shoaib Ahmed Department of Biochemistry, Federal Urdu University of Arts, Science and Technology, Karachi, Pakistan.
Anila Bibi Neurochemistry and Biochemical Neuropharmacology Research Unit, Department of Biochemistry, University of Karachi, Karachi, Pakistan.
Syeda Rabab Zehra Neurochemistry and Biochemical Neuropharmacology Research Unit, Department of Biochemistry, University of Karachi, Karachi, Pakistan.
Jaweria Kanwal Neurochemistry and Biochemical Neuropharmacology Research Unit, Department of Biochemistry, University of Karachi, Karachi, Pakistan.
Ayesha Ahmed Soomro Neurochemistry and Biochemical Neuropharmacology Research Unit, Department of Biochemistry, University of Karachi, Karachi, Pakistan.
Mehreen Neurochemistry and Biochemical Neuropharmacology Research Unit, Department of Biochemistry, University of Karachi, Karachi, Pakistan.
Zohra Siraj Neurochemistry and Biochemical Neuropharmacology Research Unit, Department of Biochemistry, University of Karachi, Karachi, Pakistan.
Nabeel Ahmed Saghir Neurochemistry and Biochemical Neuropharmacology Research Unit, Department of Biochemistry, University of Karachi, Karachi, Pakistan.
Abstract
Paroxetine belongs to the A phenylpiperidine class of selective serotonin reuptake inhibitors (SSRIs). Compared to other SSRIs such as sertraline, fluoxetine, and fluvoxamine, paroxetine, demonstrates greater selectivity as well as potency. Its pharmacokinetic profile makes it highly suitable for clinical application, having a half-life approximately 24 hours and absence of active metabolites. Similar to other SSRIs, it has minimal clinically relevant drug interactions. Stressful conditions exert a complex influence on neural and physiological processes, often contributing to depression and anxiety. Evidence from both clinical and experimental research indicates that paroxetine effectively reduces moderate to acute depression and related anxiety symptoms, with an onset of action comparable to tricyclic antidepressants. To ascertain paroxetine's anxiety-reducing and appetite-enhancing effects in a rat model of unexpected stress. Male adult rats were divided into stressed as well as unstressed groups. Animals received paroxetine (10 mg/kg/day) for a period of 14 days, one hour prior to stress exposure. Behavioral outcomes, including food intake and elevated plus maze performance, were recorded after the first administration and at weekly intervals. The study investigated whether paroxetine could attenuate stress-induced anorexia and behavioral impairments. Prolonged moderate anxiety produced significant changes in the behavior, which were mitigated by recurrent paroxetine treatment. Stressed animals exhibited depressive-like behaviors, attenuated by paroxetine administration. Food intake in unstressed groups treated with paroxetine was significantly higher than in stressed animals treated with saline treatment, demonstrated hyperphagic effects, with food intake being significantly higher in unstressed than in stressed animals. Paroxetine administration produced significant anxiolytic effects in the elevated plus maze, particularly in unstressed animals.
Publication Details
Page(s) 909-915
DOI DOI not available
Published Journal: International Journal of Biology and Biotechnology, Volume: 22, Issue: 4, Year: 2025

Request the full text from PASTIC

Keywords
Serotonin, Anorexia, Paroxetine, prolonged unexpected stress, Depressed behavior, SSRIs
References
Blier P.,C. de Montigny P. .1994 .Current advances and trends in the treatment of depression. Trends of Pharmacological Sciences, 15(7) : 220-226.
Blier P.,Chaput Y. .1990 .A role for the serotonin system in the mechanism of action of antidepressant treatments: preclinical evidence. Journal of Clinical Psychiatry, 51(Suppl) : 14-20.
Byerley S. C.,Risch S. C. .1985 .Depression and serotonin metabolism: rationale for neurotransmitter precursor treatment. Journal of Clinical Psychopharmacology, 5(4) : 191-206.
Batool F.,Kamal A.,Sattar M.,Shah A. H.,Ahmed S. D.,Saif Z. S.,Haleem D. J. .2011 .Evaluation of antidepressant-like effects of aqueous extract of Sea Buckthorn (Hippophae rhamnoides L. ssp. turkestanica) fruits in experimental models of depression. , 43(3) : 1595-1599.
Geoffrey B. Varty ,Cohen-Williams Galen J. Carey.,Plus-Maze I .2002 .Behavioral Characterization and Pharmacological Validation. , 27 : 357-370.
Handley S. L,Mithani S. .1984 .Effects of α-adrenoreceptor agonists and antagonists in a maze-exploration model of 'fear'-motivated behaviour. Naunyn-Schmeideberg's Arch Pharmacol. , 327 : 1-5.
Katz R. J.,Roth K. A.,Carroll B. J. .1981 .Acute and chronic stress effects on open field activity in the rat: Implications for a model of depression. Neuro Sci. Biobehav. Res., 5(2) : 247-251.
Muscat R.,Towell A.,Willner P. .1988 .Changes in dopamine autoreceptor sensitivity in an animal model of depression. Psychopharmacology, 94(4) : 545-550.
Preskorn S.,Stanga C. Y.,Feighner and R. Ross J. P. .2004 .. Antidepressants: Past, Present and Future, : 540.
Leonard B. E. .1996 .New approaches to the treatment of depression. Clinical Psychiatry, 57(Suppl) : 26-33.
Meltzer H. .1989 .Serotonergic dysfunction in depression. British Journal of Psychiatry, 8(Suppl) : 25-31.
Montgomery K. C. .1958 .The relation between fear induced by novel stimulation and exploratory behavior. J Comp Physiol Psychol., 48 : 254-260.
Ottenweller J. E.,Servatius R. J.,Tapp W. N.,Drastal S. D.,M. T. Bergen B. H. Natel- son S. D.,S. S. D.,Chopin P.,File S. E.,Briley M. .1985 .Validation of open:closed arm entries in an elevated plusmaze as a measure of anxiety in the rat. J Neurosci Meth., 14 : 149-67.
Kulikov A,Aguerre S.,Berton O.,Ramos A.,Mormède P.,Chaouloff F. .1997 .Central serotonergic systems in the spontaneously hypertensive and Lewis rat strains that differ in the elevated plus-maze test of anxiety. The Journal of Pharmacology and Experimental Therapeutics, 281(2) : 775-784.
Poirier M. F.,Boyer P. .1999 .Venlafaxine and paroxetine in treatment-resistant depression. Double-blind, randomised comparison. British Journal of Psychiatry, 175(1) : 12-16.
Risch S. C.,C. B. Nemeroff S. C. .1992 .Neurochemical alterations of serotonergic neuronal systems in depression. Journal of Clinical Psychiatry, 53(Suppl) : 3-7.
Rowlett J. K.,Mattingly and M. T. Bardo B. A. .1991 .Neurochemical and behavioral effects of acute and chronic treatment with apomorphine in rats. , 30 : 191-197.
0

Citations

0

Downloads

35

Views